1207853-31-3

Basic information

• Product Name: 5-dibroMo-2-Methoxypyrazine
• Synonyms: 5-dibroMo-2-Methoxypyrazine;3,5-DibroMo-2-Methoxypyrazine
• CAS NO: 1207853-31-3
• Molecular Formula: C5H4Br2N2O
• Molecular Weight: 267.90606
• Mol File: 1207853-31-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-dibroMo-2-Methoxypyrazine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-dibroMo-2-Methoxypyrazine(1207853-31-3)
• EPA Substance Registry System: 5-dibroMo-2-Methoxypyrazine(1207853-31-3)

Safety Data

• Hazardous Substances Data: 1207853-31-3(Hazardous Substances Data)

Upstream product

• 186581-53-3 diazomethane 
• 21943-15-7 3,5-dibromo-2-hydroxylpyrazine 
• 67-56-1 methanol 
• 24241-18-7 2-amino-3,5-dibromopyrazine 

Downstream Products

• 1334135-54-4 5-bromo-3-hydrazinyl-2-methoxypyrazine 
• 1334135-57-7 5-bromo-8-methoxy-[1,2,4]triazolo[4,3-a]pyrazine 

Relevant articles and documents

HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

The invention relates to a novel heterocyclic compound inhibiting a cyclin-dependent kinase (CDK) and a pharmaceutical composition comprising the same as an effective ingredient. The heterocyclic compound according to the present invention or pharmaceutically acceptable salt thereof can be effectively used in treating or preventing cancers, degenerative brain diseases, etc.

TRIAZOLOPYRAZINONES AS PDE1 INHIBITORS

The present invention provides triazolopyrazinones as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE

The present invention relates to compounds and methods which may be useful as inhibitors of H4R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.

6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS

The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, their synthesis, and their use as CHK-1 inhibitors.